Margaret MacMillan, M.D.

Associate Professor
BMT Fellowship Director
Mayo Mail Code 484
420 Delaware St. SE
Minneapolis, MN 55455
Phone: (612) 626-2778
Fax: (612) 626-2815
macmi002@umn.edu
Preferred method of contact: Email

Dr. MacMillan is an Assistant Professor of Pediatrics in the Division of Hematology-Oncology and Blood and Marrow Transplantation and attends on the Pediatric Blood and Marrow Transplantation service. Dr. MacMillan is the Clinical Medical Director of the Pediatric BMT Program and the Medical Director of the Unrelated Donor Program at the University of Minnesota.

Dr. MacMillan received her MSc degree at the University of Toronto in 1989 and her M.D. degree at the University of Toronto in 1991. She completed her internship residency in Pediatrics, and post-doctoral fellowship in Hematology-Oncology at the University of Toronto School of Medicine in 1997. She then completed a Blood and Marrow Transplant fellowship at the University of Minnesota in 1999 after which she joined the faculty.

Dr. MacMillan's research is focused on the development and implementation of novel strategies for preventing the immunologic complications of allogeneic hematopoietic stem cell transplantation. She is the Principal Investigator of 10 phase I/II clinical trials at the University of Minnesota. In collaboration with Bruce Blazar, M.D., she is studying the safety and efficacy of T regulatory cells to prevent graft-versus-host disease. Dr. MacMillan is co-director with John Wagner, M.D. of the University of Minnesota Fanconi Anemia Comprehensive Care Clinic, which follows the largest number of Fanconi anemia patients in the world. Dr. MacMillan has authored more than 30 articles and book chapters on the subject of hematopoietic stem cell transplantation, and is a member of numerous professional societies.  She is Board Certified in Pediatrics.

Honors and Awards

• 1986 Ontario Graduate Scholarship
• 1987 Open Scholarship, University of Toronto
• 1988 Life Sciences Graduate Degree Completion Award, University of Toronto
• 1990 Charles E. Snelling Scholarship in Pediatrics, University of Toronto
• 1991 Schilling Scholarship Award in Pediatrics, University of Toronto
• 1997 Cooley's Anemia Fellowship, Boston, Massachusetts
• 2000 Irvine McQuarrie Research Scholar, University of Minnesota

Research Interests

1. Acute Graft-Versus-Host Disease
   • T regulatory cells to prevent GVHD
   • Novel pharmacologic agents/ regimens
2. Fanconi anemia
   • Novel preparative therapies
   • Gene therapy - multipotent adult stem cell
   • Mechanisms to speed immune recovery and reduce infection after transplantation
3. Juvenile Myelomonocytic Leukemia
   • Novel phase I agents
   • Novel preparative therapies

Selected Recent Publications

Tan PL, Wagner JE, Auerbach AD, DeFor TE, Slungaard A, and MacMillan ML. Successful engraftmment without radiation after fludarabine-based regimen in Fanconi Anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatric Blood and Cancer.  46:630-636, 2006.

Barker J, Hough RE, van Burik J, DeFor T, MacMillan ML, O’Brien MR, Wagner JE.  Serious Infections After Unrelated Donor Transplantation in 136 Children: Impact of Stem Cell Source.  Biol  Blood Marrow Tranplant. 11:362-70 (005.

MacMillan ML and Wagner JE. Hematopoietic cell transplantation on congenital bone marrow failure. Current Opinions in Oncology, 17:106-113, 2005.

Pinto-Cardoso SM, DeFor TE, Tilley LA, Bidwell JL, Weisdorf DJ and MacMillan ML. Patient interleukin-18 GCG haplotype associates with improved survival and decreased transplant-related mortality after unrelated-donor bone marrow transplantation. British Journal of Haematology, 126:704-710, 2004.

MacMillan ML, Radloff G.A, DeFor TE, Weisdorf DJ and Davies SM. IL-1 genotype and outcome of unrelated donor bone marrow transplantation. British Journal of Haematology, 121:597-604,2003.

Kumar AR, Wagner JE, Auerbach AE, Coad JE, Dietz CA, Schwarzenberg SJ and MacMillan ML. Fatal intrahepatic hemorrhage due to androgen-related hepatic adenomas after hematopoietic cell transplantation. Journal of Pediatric Hematology/Oncology, 26(1):16-18, 2004.

MacMillan ML, Radloff GA, DeFor TE, Weisdorf DJ and Davies S.M. High producer IL-2 genotype increases risk for acute GVHD after unrelated donor bone marrow transplantation. Transplantation, 76:1758-1762, 2003.

Wagner JE, MacMillan ML, Auerbach AD.  Hematopoietic cell transplantation for Fanconi Anemia.  In: Blue KG, Forman SJ, Appelbaum FR, eds. Thomas, Hematopoietic Cell Transplantation.  Blackwell Publishing Ltd, Oxford, 2003.

MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NKC, Davies SM, Blazar BR. Response of 443 patients to steroids as primary therapy for acute graft-versus-host-disease: Comparison of grading systems. Biology of Blood and Marrow Transplantation, 8:387-394,2002.

MacMillan ML, Goodman JL, Defor TE and Weisdorf DJ. Fluconazole to Prevent Fungal Infections in Bone Marrow Transplantation Patients: Randomized Comparative Trial of High Versus Reduced Dose and Determination of the Value of Maintenance Therapy. American Journal of Medicine, 112:369-379,2002.

MacMillan ML, Weisdorf DJ, Davies SM, DeFor TE, Burns LJ, Ramsay NK, Wagner JE and Blazar BR. Early Antithymocyte Globulin Therapy Improves Survival in Patients With Steroid-Resistant Acute Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 8:40-46,2002.

MacMillan ML, Auerbach AD, Davies SM, DeFor TE, Gillio A, Giller R, Harris R, Cairo M, Dusenberry K, Hirsch B, Ramsay NKC, Weisdorf DJ and Wagner JE. Hematopoietic cell transplantation in patients with Fanconi Anemia using non-genotypically identical donors: Results of a TBI dose escalation trial. British Journal of Haematology 108:1-10, 2000.